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Abstract
Nonviral gene delivery methods are advantageous over viral vectors in terms of safety, cost, and
flexibility in design and application, but suffer from lower gene transfer efficiency. In addition to
modifications to nucleic acid design and nonviral carriers, new tools are sought to enhance trans-
fection. Priming is the pharmacological modulation of transfection efficiency and transgene
expression, and has demonstrated transfection increase in several compounds, for example, chlor-
oquine and glucocorticoids. To develop a library of transfection priming compounds, a high-
throughput screen was performed of the NIH Clinical Collection (NCC) to identify clinical com-
pounds that prime polyethylenimine (PEI) transfection. HEK293T cells were treated with priming
compounds, then transfected with enhanced green fluorescent protein (EGFP)-encoding plasmid by
PEI. After 48-hr culture, primed and transfected cells were assayed for transfection, cell prolifera-
tion, and cell viability by fluorescence measurement of EGFP reporter, Hoechst 33342 nuclei stain,
and resazurin metabolic assay. From the microscope image analysis and microplate measurements,
transfection fold-changes were determined, and compounds resulting in statistically significant
transfection fold-change were identified. NCC compounds were clustered using PubChem finger-
print similarity by Tanimoto coefficients in ChemmineTools. Fold-changes for each compound were
linked to drug clusters, from which drug classes that prime transfection were identified. Among the
identified drugs classes that primed transfection increases were antioxidants, GABAA receptor
modulators, and glucocorticoids. Resveratrol and piceid, stilbenoid antioxidants found in grapes,
and zolpidem, a GABAA modulator, increased transfection nearly three-fold. Literature indicate
interaction of the identified transfection priming drug clusters with mitochondria, which may modu-
late mitochondrial dysfunction known to be associated with PEI transfection.
K E YWORD S
high-throughput screen, mitochondrial dysfunction, NIH Clinical Collection, nonviral gene delivery,
polyethylenimine toxicity, priming transfection
1 | INTRODUCTION
Gene delivery, the transfer of exogenous nucleic acids into cells to modify
gene expression, can be accomplished with either viral or nonviral meth-
ods. Viral transduction is highly efficient in vitro and in vivo, however,
transduction is limited by design constraints and safety concerns, a few of
which include: size of transgene,1 host immune response,2 and insertional
mutagenesis.3 Nonviral gene delivery methods often make use of chemical
strategies that rely on cationic carriers, which can associate with nucleic
acids to form complexes that achieve gene delivery.1 These materials offer
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advantages over viral methods of gene delivery, in safety, cost, fabrication,
and flexibility in design and application. However, compared to viral meth-
ods, chemical methods of nonviral gene delivery suffer from lower trans-
fection efficiency, especially in vivo.4 Many barriers to successful
transfection exist, with each contributing to the overall low efficiency of
nonviral gene delivery. Systemic barriers include serum stability, clearance,
and targeting,5 while cellular barriers to efficient transfection include cellu-
lar internalization, endosomal escape, nuclear transport, nuclear import,
and transcriptional and translational regulation.5
Carrier properties and optimization are the most important determi-
nants in the efficiency of chemical nonviral gene delivery strategies in
terms of facilitating delivery to and into cells. In 1995, Polyethylenimine
(PEI), a cationic polymer, demonstrated successful transfection in vitro
and in vivo in multiple cell types.6 General optimization of PEI transfec-
tion is accomplished through tuning of N:P ratio, the ratio of amine
groups in the PEI polymer to phosphate groups in the nucleic acid. N:P
ratio determines the overall size and charge of these PEI-nucleic acid
complexes and defines their ability to circulate in serum, internalize into
cells, and escape endosomes, and thus are primary determinants of PEI
transfection efficiency.6–8 Optimized PEI transfection achieves efficiency
of 50–80% in vitro depending on molecular weight of PEI, plasmid, and
cell type,8 compared to the 100% efficiency achieved by some opti-
mized viral transduction methods in vitro.9 Most attempts to improve
chemical methods of nonviral gene delivery involve modification of the
carriers, such as modification of PEI with PEG and targeting ligands8 to
increase serum stability and circulation or enhance specific uptake,
respectively. Although nonviral gene delivery methods continue to be
improved, they have not exceeded viral methods in gene transfer effi-
ciency and sustained expression in clinical trials.10
We propose pharmacological priming as an adjuvant strategy,
which can, in conjunction with innovations in carrier and nucleic acid
design, achieve clinically relevant nonviral gene transfer efficiency and
expression. Priming refers to the treatment of cells with chemical com-
pounds before, during, or after delivering carrier-nucleic acid complexes
to cells in order to improve some aspect of the gene transfer process.
Priming enhancement of transfection efficiency and transgene expres-
sion can be achieved through direct modulation of the barriers to gene
delivery, or indirectly through modulation of the cellular response to
transfection in terms of toxicity and altered gene expression.
Priming compounds for gene delivery have been used in the litera-
ture, mostly in the context of probing biological mechanisms of trans-
fection. For example, chloroquine is an antimalarial compound that has
been demonstrated to enhance nonviral gene delivery in transfections
across several nanoparticle carrier formulations,11 through buffering of
endosomes, aiding complexes in escaping endosomes and avoiding
lysosomal degradation.11,12 Glucocorticoid priming has been demon-
strated to enhance viral and nonviral gene delivery across multiple cell
types.13–15 Recent work showed that priming human mesenchymal
stem cells (hMSCs), a primary cell type that is typically difficult to trans-
fect, with dexamethasone (a synthetic glucocorticoid), increased trans-
fection efficiency and transgene expression up to 10-fold across
multiple donors.15 Furthermore, pharmacological priming, with activa-
tors and inhibitors of genes previously identified as differentially
expressed in successfully versus unsuccessfully transfected HEK293T
cells, was shown to enhance or decrease transgene expression,16–19
demonstrating that genomic targets can be modulated by priming to
enhance nonviral gene delivery. Several of these genes were related to
cell stress, indicating that in addition to overcoming the primary bar-
riers to transfection, nonviral gene delivery strategies may need to
modulate the overall cellular response to transfection to achieve higher
transfection efficiency and more sustained transgene expression.
While broad applicability of transfection priming to different car-
riers, nucleic acids, and cell types has not been established, a next step
in the development of this strategy is to search for other compounds
that have priming effects. Priming strategies can theoretically be used
to modulate any of the known barriers to transfection, from transport
mechanisms into the cell and to the nucleus, to transcriptional and
translational regulation and toxicity. To broadly search for potential pri-
ming mechanisms, a high-throughput, drug repurposing approach was
taken toward generating a library of compounds from the NIH Clinical
Collection (NCC)20 that possess clinically relevant bioavailability and
biocompatibility, and whose priming effects could be studied and used
to develop effective nonviral gene delivery strategies.
2 | MATERIALS AND METHODS
2.1 | HEK293T culture and transfection reagents
HEK293T cells (ATCC, Manassas, VA) were cultured in T-25 flasks
(Thermo Fisher Scientific, Waltham, MA) in Dulbecco’s Modified Eagle
Medium (DMEM) (Life Technologies, Carlsbad, CA) completed with
10% fetal bovine serum (Life Technologies), 1% Penicillin/Streptomycin
(Life Technologies), and 1% sodium pyruvate (Life Technologies). Cells
were incubated at 378C, 5% CO2, and passaged using 1 mM EDTA in
PBS (Sigma-Aldrich, St. Louis, MO) at 75–85% confluence approxi-
mately every 48 hrs.
The pEGFPLuc plasmid delivered in this transfection screen enco-
des for a fusion protein of enhanced green fluorescent protein (EGFP)
and luciferase, driven by a CMV promoter (Clontech, Mountain View,
CA). pEGFPLuc was propagated in E. coli, selected by kanamycin treat-
ment, isolated using Qiagen Giga Prep kits (Qiagen, Valencia, CA), pre-
pared in endotoxin-free TE buffer at 1 mg/ml, and subsequently stored
in frozen aliquots at 2208C. PEI (25 kDa branched PEI, Sigma-Aldrich)
was used for this transfection screen. PEI was prepared at 1 mg/ml, in
0.1 M sodium bicarbonate (pH 8.2), then stored in aliquots at 2808C.
2.2 | Priming compounds and fluorescence assay
reagents
The NIH NCC, which contains 725 compounds screened for transfec-
tion priming, were received in ten, 96-well plates, with 10 ll of each
compound at 10 mM in dimethyl sulfoxide (DMSO). To prepare ali-
quots, 2 ll of each compound were prepared in four 96-well aliquot
plates per original NCC plate, and kept frozen at 2208C. Hoechst
33342 fluorescent dye was used to stain cell nuclei and enable cell-
count by processing of fluorescence microscope images, while
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resazurin was used as a fluorescent metabolic indicator in this screen.
For cell staining, Hoechst 33342 stock solution was prepared from
lyophilized powder (Sigma-Aldrich), dissolved in ddH20 at a concentra-
tion of 10 mg/ml, and stored at 48C. Stock resazurin solution was pre-
pared from lyophilized resazurin sodium salt powder (Sigma-Aldrich),
dissolved in PBS at a concentration of 10 mg/ml, and stored at 48C.
2.3 | Transfection priming high-throughput screen
HEK293T cells were detached from culture flasks by EDTA, counted by
hemocytometer, and seeded at 25,000 cells/cm2 (8,000 cells per well in
80 ll) into 96-well plates. Four plates were seeded for each of the 10
plates of the NCC collection screened, for duplicate testing of the com-
pounds at 5 and 50 lM. Seeded plates were cultured at 378C, 5% CO2,
and approximately 17 hr after seeding two plates with cells, 40 ll of
each NCC compound were delivered into corresponding wells of both
seeded plates, at either 5 or 50 lM final well volume concentration.
Two columns (16 wells) of each plate received equivalent DMSO %
instead of NCC compound as priming vehicle controls. The primed
plates were then incubated for one hour at 378C, 5% CO2 before trans-
fection. For transfection, PEI was diluted in 1X Tris-buffered saline
(TBS) and added to pEGFPLuc diluted in 1X TBS. Complexes were
formed at an optimized (data not shown) N:P of 15 to deliver 0.17 lg
of pEGFPLuc in 21 ll of TBS to each well 1 hr after priming, followed
by incubation at 378C, 5% CO2 for 48 hr before staining and imaging.
The primed and transfected HEK293T plates were stained with
Hoechst and resazurin fluorescent dyes to enable subsequent nuclei
counts and viability assessments, respectively, multiplexed with the
EGFP fluorescent reporter for transgene expression. Staining solution
consisted of 17.5 lg/ml Hoechst 33342 and 10 lg/ml resazurin in Flu-
orobrite DMEM (Thermo Fisher Scientific). After rinsing cells with PBS,
100 ll of the staining solution was added to each well, followed by
incubation for 30 min at 378C, 5% CO2.
After incubation with the staining solution, plates were imaged using
a DMI3000B manual inverted microscope with DFC340FX digital cam-
era, EL-6000 mercury halide lamp for fluorescence excitation, and LAS
software V4.0 for digital image viewing and capture (Leica, Buffalo Grove,
IL). Filters for excitation and detection at the EGFP and Hoechst wave-
lengths (488 nm/509 nm and 355 nm/465 nm, respectively) were used
to take monochrome images of their fluorescence, in addition to phase
contrast images. Images were taken with a 5x objective at the center of
each well in 8-bit TIFF format and 1600x1200 pixels, with each pixel
having a greyscale value from 0 to 255. Consistent fluorescence excita-
tion lamp intensity and camera exposure settings were used to allow for
comparison of image intensities between wells in the same plate.
Macros in ImageJ,21 a Java-based image processing program, were
used to automate the mean fluorescence intensity measurements and
maxima counts for the processing of the thousands of images acquired
over the course of the screen. Average grey values of the Hoechst and
EGFP images were determined using the “Measure” plugin in ImageJ.
Total cells and transfected cells were counted for each well using the
“Find Maxima” plugin to count Hoechst stained nuclei and EGFP
expressing cells, respectively. The noise tolerance of the “Find Maxima”
plugin was adjusted to optimize detection and minimize misidentifica-
tion of nuclei and EGFP cells.
In addition to microscope imaging, EGFP, Hoecshst, and resazurin
fluorescence were measured by Synergy H1 plate reader (BioTek,
Winooski, VT), with excitation/emission settings of 475 nm/509 nm,
355 nm/464 nm, and 545 nm/590 nm, and gain settings of 100, 50,
and 50, respectively. Nine measurements were taken per well in a
three by three array equally spaced within the well, from which mean
intensities were calculated.
2.4 | Data processing
The goal of the data processing was to determine compounds that pro-
duced fold-changes in transfection, compared to vehicle controls. To
reduce potential fold-change bias resulting from initial seeding density
variation, vehicle control wells that had total cell-counts less than the
mean cell-count of vehicles controls as a whole for the plate were dis-
carded from consideration for calculations of fold-changes. There
remained up to 16 vehicle control wells per plate in the screen after fil-
tering (n16). Image and plate reader data for each well were then
normalized by cell-count and their fold-changes determined relative to
these filtered vehicle control wells. EGFP measurements were normal-
ized into two separate measures: normalization by total cell-count and
normalization by transfected cell-count. Hoechst and resazurin meas-
urements were normalized by total cell-count.
Cytotoxicity filters were implemented to remove from consideration
compounds that were too toxic at the tested concentrations to warrant
further consideration in the screen. In the first toxicity filter, compounds
with normalized Hoechst-count fold-change of less than 0.2 were dis-
carded. In the second toxicity filter, compounds with Hoechst-count
fold-change two or three standard deviations below the plate-wide aver-
age of Hoechst-count fold-changes greater than 0.2 were also discarded.
A more stringent toxicity filter was used for the 5 lM concentration
(two standard deviations) than the 50 lM (three standard deviations).
The rationale behind this difference is that the 5 lM conditions contain
a lower concentration of priming compound and of the DMSO vehicle,
resulting in less cytotoxicity than the 50 lM conditions; therefore, a
more stringent filter was applied to the lower concentration.
Each compound was tested in a single well per plate, in duplicate
plates, at 5 and 50 lM concentrations. The duplicate normalized fold-
changes of these single wells from duplicate plates were grouped
(n52) for unpaired one-tailed t tests against grouped filtered vehicle
controls from the same duplicate plates (n32 filtered vehicle control
wells from the duplicate plates associated with the tested compound
of n16 control wells each), to obtain p values for EGFP, Hoechst,
and resazurin measurements of each compound at each concentration,
with an a-value for significance of 0.05. For each well, the assumption
of equal or unequal variance in the t test was estimated by F-test (one-
tailed, a50.05) for equality of variances between tested compound
and control wells. One-tailed t tests were used to score the screen
fold-changes, in spite of expected higher false positive rates than two-
tailed tests, to err on the side of caution in not rejecting potential pri-
ming compounds, and rely on the clustering results to support the
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single compound hit selection as well as future investigation of the
screen hits to reject false positives.
Given the large number of drugs to be tested in the NCC, we
chose to use a sample size of two for each concentration of each drug.
Two is the minimum number of samples for performing a t test22; more
importantly, the goal of this screen was to be the initial step in the
search for clinical compounds that could be repurposed toward trans-
fection priming, using a high throughput methodology to deliberately
test in small sample sizes, sacrificing power for breadth of small mole-
cules tested from the NCC.
2.5 | Hit selection and compound clustering
All NCC compounds that exhibited significant fold-increases or fold-
decreases in transfection, at either 5 or 50 lM, and were not filtered
for cytotoxicity, were identified as hits (a-value for significance of
TABLE 1 Highest fold-changes in transfection priming hits at 5mM of NCC compounds
Compound Drug type Transfectiona Cell-countb Hoechst-intensityc Resazurin-intensityd
Transfection
fold-increase
Zolpidem tartrate GABA receptor
modulator
3.05 0.52
Resveratrol Stilbenoid 3.04 0.55
Tropisetron
hydrochloride
Serotonin receptor
antagonist
2.67 0.97 0.91 1.07
Tranilast Anti-allergy 2.17 0.74 1.11 1.29
Lansoprazole Proton-pump
inhibitor
2.13 0.72 1.13 1.42
Nobiletin Flavonoid 2.08 0.61 1.23 1.21
Nitrazepam GABA receptor
modulator
2.03 0.53
Enalaprilat Angiotensin-
converting-enzyme
inhibitor pro-drug
2.00 0.55 1.35 1.51
Droperidol Dopamine receptor
antagonist
1.95 0.52
Mestanolone Androgen hormone 1.93 0.61 1.26
Transfection
fold-decrease
Epigallocatechin
gallate
Flavonoid 0.08 1.37 0.88
Ampiroxicam Nonsteroidal
anti-inflammatory drug
0.31 0.93 0.91 1.14
Nimodipine Calcium channel
blocker
0.35 0.90
(2)-Cotinine Nicotine metabolite 0.41 0.87 1.16
Ramipril Angiotensin-
converting-enzyme
inhibitor
0.42 0.98 0.92
Desloratadine Anti-histamine 0.50 0.86 1.19
Crotamiton Anti-itch 0.50 0.98 0.93
Guanidine Amino acid
metabolite
0.52 0.93 1.12
Letrozole Estrogen synthesis
inhibitor
0.52 1.00 0.87
Fluphenazine
hydrochloride
Dopamine receptor
antagonist
0.53 0.85 1.08 1.17
Note. Empty values indicate nonsignificant fold-change.
aTransfection fold-changes were calculated from duplicate averages of EGFP fluorescence, measured by EGFP cell-count (image processing) or EGFP
intensity (plate reader and image processing), relative to the same measurement averaged from the vehicle controls in each compound’s respective
plates. These measurements were normalized in two separate ways, total cell-count (determined by Hoechst-count), and transfected cell-count (deter-
mined by EGFP-count), for measurement of transfection per cell as well as transfection per transfected cell.
bCell-count fold-changes were calculated from duplicate averages of image processing measurements of Hoechst-count relative to the average
Hoechst-count measurements of vehicle controls in each compound’s respective plates. Cell-count fold-changes are shown for each hit presented as a
general toxicity reference, not to imply significant increase or decrease.
cHoechst-intensity fold changes were calculated from duplicate averages of plate reader or image processing measurements of Hoechst-intensity nor-
malized by total cell-count (determined by Hoechst-count), relative to the average Hoechst-intensity measurements of vehicle controls in each com-
pound’s respective plates.
dResazurin-intensity fold changes were calculated from duplicate averages of plate reader measurements of resazurin intensity normalized by cell-count
(determined by Hoechst-count), relative to the average resazurin-intensity measurements of vehicle controls in each compound’s respective plates.
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0.05). In addition, the hit selection of this screen also included examina-
tion of overall transfection fold-changes of grouped drug clusters to
identify drug classes for which the majority of compounds were hits
for transfection priming effects. NCC compounds were clustered
using the Chemmine Tools web platform for comparison of Pub-
Chem fingerprints by Tanimoto coefficients.23 Hierarchical clustering
was used to create a dendrogram based on single linkage fingerprint
similarity, while binning clustering grouped compounds based on
single linkage fingerprint similarity determined by Tanimoto coeffi-
cient thresholds of 0.4 to 0.9 (higher coefficient indicates greater
fingerprint similarity).
EGFP, Hoechst, and resazurin measurement fold-changes for each
compound at each concentration were linked to the NCC clusters by a
custom Perl script, which parsed the data files and grouped the data
into average fold-changes for each binned cluster. To analyze the hits,
the compounds which primed the 10 highest fold-increases or fold-
TABLE 2 Highest fold-changes in transfection priming hits at 50 mM of NCC compounds
Compound Drug type Transfectiona Cell-countb Hoechst-intensityc Resazurin-intensityd
Transfection fold-
increase
Tranilast Anti-allergy 3.63 0.55 1.24
Piceid Stilbenoid 2.63 0.69 1.17
5-Fluorocytosine Pyrimidine analogue 2.54 0.52 1.50 1.58
Cinanserin Serotonin receptor
antagonist
2.53 0.63 1.41
Zardaverine Phosphodiesterase
inhibitor
2.26 0.55 1.36
Nateglinide ATP potassium
channel closer
2.08 0.51 1.23 1.21
Eryped Macrolide antibiotic 1.99 0.72 1.26 1.26
Mestinon Cholinesterase
inhibitor
1.83 0.77 1.21 1.23
Acyclovir DNA polymerase
inhibition (anti-viral)
1.78 0.60
Stiripentol GABA receptor
modulator
1.77 0.72 1.23
Transfection fold-
decrease
Epigallocatechin
gallate
Flavonoid 0 0.80
Cefixime trihydrate b-lactam antibiotic 0.017 1.45 0.84
Cefdinir b-lactam antibiotic 0.032 1.35 0.88
Cefuroxime b-lactam antibiotic 0.039 1.39
Rolitetracycline Tetracycline
antibiotic
0.063 1.42 0.86
Cefatrizine propy-
lene glycol
b-lactam antibiotic 0.095 1.75 0.78
Tetracycline Tetracycline
antibiotic
0.139 1.08 0.85
Taxifolin-(1) Flavonoid 0.162 1.22 0.87
(1/2)-Epinephrine
hydrochloride
Adrenergic receptor
agonist
0.35 1.36 0.83
Isoquercitrin
Hyperoside
Flavonoid
Flavonoid 0.358 1.68 0.86
Note. Empty values indicate nonsignificant fold-change.
aTransfection fold-changes were calculated from duplicate averages of EGFP fluorescence, measured by EGFP cell-count (image processing) or EGFP
intensity (plate reader and image processing), relative to the same measurement averaged from the vehicle controls in each compound’s respective
plates. These measurements were normalized in two separate ways, total cell-count (determined by Hoechst-count), and transfected cell-count (deter-
mined by EGFP-count), for measurement of transfection per cell as well as transfection per transfected cell.
bCell-count fold-changes were calculated from duplicate averages of image processing measurements of Hoechst-count relative to the average
Hoechst-count measurements of vehicle controls in each compound’s respective plates. Cell-count fold-changes are shown for each hit presented as a
general toxicity reference, not to imply significant increase or decrease.
cHoechst-intensity fold changes were calculated from duplicate averages of plate reader or image processing measurements of Hoechst-intensity nor-
malized by total cell-count (determined by Hoechst-count), relative to the average Hoechst-intensity measurements of vehicle controls in each com-
pound’s respective plates.
dResazurin-intensity fold changes were calculated from duplicate averages of plate reader measurements of resazurin intensity normalized by cell-count
(determined by Hoechst-count), relative to the average resazurin-intensity measurements of vehicle controls in each compound’s respective plates.
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decreases in transfection at either 5 or 50 lM were determined (Tables
1 and 2), which were used to determine clusters of interest (Figure 2).
The grouped fold-changes in transfection of the clusters of interest
were examined to determine clusters for which the majority of member
compounds were hits for priming transfection (Table 3).
2.6 | Preliminary verification experiment
Preliminary verification experiments were performed for three of the
priming compounds identified (resveratrol, epigallocatechin gallate
[EGCG], and corticosterone), testing these hit compounds at 5 lM in
triplicate in 48-well plates, with number of seeded cells and volumes of
reagents added scaled by the well surface area increase from 96-well
plates (see complete description of the method in Supporting Informa-
tion). Transgene expression was assayed by luciferase assay, normal-
ized by total protein measured by BCA assay, in units of relative light
units per milligram of total protein.
3 | RESULTS
HEK293T cells were primed with 725 compounds from the NCC,
transfected with a plasmid encoding for an EGFP reporter protein using
25 kDa branched PEI, and assayed by fluorescence microscope imaging
and plate reader measurement of EGFP, Hoechst 33342, and resazurin,
to screen for compounds that enhance or decrease transfection, with-
out significant toxicity (see Supporting Information Tables S1–S4 for
the EGFP and Hoechst fluorescence intensity and count data of the
compounds listed in Tables 1 and 2). With an a-value for significance
of 0.05 for average fold-changes of duplicates and two toxicity filters,
the screen returned 441 priming compound hits at 5 mM with EGFP
fold-change ranging from 0.077 to 4.29, and Hoechst-count fold-
changes ranging from 0.22 to 1.45 (Figures 1A and 1B). There were
333 hits at 50 mM, with EGFP fold-change ranging from 0 to 3.63,
and Hoechst-count fold-changes ranging from 0.25 to 1.75 (Figures 1C
and 1D).
TABLE 3 Average fold-changesa of transfection priming hits from clusters of interest (Figure 2)
Transfection fold-increase hits Transfection fold-decrease hits
Cluster (#) Concentration # of hits Transfectionb Cell-countc # of hits Transfectionb Cell-countc
Hormones (54) 5 mM 34* 1.4360.22 0.736 0.15 3 0.8160.07 0.936 0.19
50 mM 15 1.3560.16 0.666 0.86 9 0.7460.12 0.846 0.24
Glucocorticoids (30) 5 mM 17* 1.3760.14 0.776 0.14 3 0.8160.07 0.936 0.19
50 mM 12 1.3760.15 0.676 0.10 3 0.8160.04 1.016 0.08
Tetracyclines (6) 5 mM 5* 1.2760.15 0.826 0.06 1 0.91 0.72
50 mM 0 3* 0.2660.27 1.076 0.36
Fluoroquinolones (8) 5 mM 5* 1.5460.24 0.646 0.17 0
50 mM 4 1.5660.25 0.636 0.11 2 0.6560.21 0.966 0.09
b-lactams (18) 5 mM 7 1.2560.17 0.936 0.13 2 0.6960.12 1.266 0.14
50 mM 5 1.2560.11 0.966 0.20 9* 0.4260.37 1.316 0.21
Cephalosporins (10) 5 mM 4 1.3360.19 0.856 0.09 1 0.61 1.36
50 mM 1 1.19 1.08 7* 0.3160.35 1.356 0.22
Macrolides (4) 5 mM 3* 1.2460.05 0.826 0.19 0
50 mM 2* 1.7260.39 0.636 0.12 2* 0.7460.18 0.856 0.42
Flavonoids and Stilbenoids (13) 5 mM 3 2.16 0.86 0.726 0.37 4 0.5260.33 1.046 0.51
50 mM 3 2.0460.61 0.696 0.09 4 0.3260.32 1.266 0.36
GABA modulators (9) 5 mM 7* 1.7460.63 0.666 0.14 0
50 mM 4 1.4160.25 0.726 0.04 0
Note. Nobileton, a flavonoid (Table 1), was not automatically grouped into the flavonoid and stilbenoid cluster (Figure 2) by the clustering algorithm; it
was manually added to the flavonoid and stilbenoid cluster for the calculation of cluster average fold-changes. Similarly, stiripentol (Table 2) and zolpi-
dem (Table 1) are GABAA receptor modulators which were not automatically clustered with the benzodiazepines (Figure 2); their fold-changes were
included into the GABAA modulator cluster for calculation of cluster average fold-changes (Table 3).
aAverage fold-changes are shown as mean6 standard deviation.
bTransfection fold-changes of hits from the same cluster were averaged. The transfection fold-changes of hits were calculated from duplicate averages
of EGFP fluorescence, measured by EGFP cell-count (image processing) or EGFP intensity (plate reader and image processing), relative to the same
measurement averaged from the vehicle controls in each compound’s respective plates. These measurements were normalized in two separate ways,
total cell-count (determined by Hoechst-count) and transfected cell-count (determined by EGFP-count), for measurement of transfection per cell as
well as transfection per transfected cell.
cCell-count fold-changes of hits from the same cluster were averaged. The cell-count fold-changes were calculated from duplicate averages of image
processing measurements of Hoechst-count relative to the average Hoechst-count measurements of vehicle controls in each compound’s respective
plates. Average cell-count fold-changes are shown for clustered hits as a general toxicity reference, not to imply significant increase or decrease.
*The majority of compounds in the cluster were hits for this fold-change.
#Denotes the number of NCC compounds in the cluster.
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At 5 mM, there were 369 hits with transfection fold-increases
(1.4560.34 fold-change, mean6 standard deviation) and 72 hits
with transfection fold-decreases (0.7360.17 fold-change) (Figures
1A and 1B). At 50 mM, there were 201 hits with transfection fold-
increases (1.4760.35 fold-change) and 132 hits with transfection
fold-decreases (0.6960.20 fold-change) (Figures 1C and 1D). To
identify the most effective priming compounds from the hundreds
of hits, the 10 compounds that resulted in the largest EGFP fold-
change, in fold-increase or fold-decrease in transfection, with
Hoechst-count fold-change no less than 0.5, were identified at 5 mM
(Table 1) and 50 mM (Table 2).
Linear regressions of EGFP fold-change versus Hoechst-count
fold-change were performed to determine correlations between trans-
fection priming and cell proliferation. There were negative correlations
between EGFP fold-increases versus Hoechst-count fold-change at
both 5 and 50 mM, with R250.467 and 0.401, respectively (Figures 1A
and 1C). There were no correlations of EGFP fold-decreases versus
Hoechst-count fold-change at either 5 or 50 mM, R250.003 and
0.056, respectively (Figures 1B and 1D).
To further analyze the transfection priming hits, drugs within the
NCC were clustered into groups of similar compounds by binning clus-
tering of PubChem fingerprints at Tanimoto clustering coefficient
thresholds ranging from 0.4 to 0.9. Cluster number increases as cluster-
ing coefficient for similarity is increased, from 300 clusters at clustering
coefficient 0.4, to 619 clusters at clustering coefficient 0.9. Based on
the identification of compounds that had the most increased or
decreased transfection fold-changes (Tables 1 and 2) clusters of inter-
est were identified (Figure 2), including antibiotics (tetracyclines,
b-lactams, and macrolides), flavonoids, stilbenoids, and GABA receptor
modulators. For these clusters of interest, average transfection fold-
changes and average Hoechst-count fold-changes were determined
(Table 3).
FIGURE 1 EGFP transfection fold-changes versus Hoechst-count fold-changes are shown for (A) 369 hits with fold-increases in transfec-
tion at 5 mM, (B) 72 hits with fold-decreases in transfection at 5 mM, (C) 201 hits with fold-increases in transfection at 50mM, and (D) 132
hits with fold-decreases in transfection at 50 mM. To examine effect of transfection priming on cell proliferation, linear regressions were
performed, demonstrating negative correlation for transfection fold-increases (AC) and no correlation for transfection fold-decreases (BD).
Regression slopes are displayed as the 95% confidence interval, along with R2 for goodness of fit. The dashed lines indicate the Hoechst-
count fold-change threshold of greater than 0.5 used in determining the largest transfection fold-increases and fold-decreases of hits in the
screen (Tables 1 and 2).
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3.1 | Antibiotics
Six antibiotics showed among the largest fold-decreases in transfection
at 50 mM in the screen, including four cephalosporin b-lactams and
two tetracyclines (Table 2), with transfection fold-decreases ranging
from 0.017 to 0.139, and associated cell-count and Hoechst-intensity
fold-changes ranging from 1.08 to 1.75-fold increase and 0.78 to 0.88-
fold decrease, respectively. One antibiotic, Eryped, was one of the ten
compounds that showed the highest fold-increase in transfection at 50
mM (Table 2), with fold-changes of 1.99, 0.72, 1.26 and 1.26, in transfec-
tion, cell-count, Hoechst-intensity, and resazurin-intensity, respectively.
From the clustering perspective, a majority of hits in the screened
b-lactam, tetracycline, and macrolide clusters were identified as hits
that showed a significant fold-decrease in transfection at 50 mM
(Table 3). No antibiotic clusters exhibited a majority of hits decreasing
FIGURE 2 Dendrograms illustrate hierarchical clustering of hormones (A), tetracyclines (B), fluoroquinolones (C), b-lactams (D), macrolides
(E), flavonoids and stilbenoids (F), and benzodiazepine GABAA receptor modulators (G), from the NCC, annotated with Tanimoto coefficients
to indicate degree of similarity between compounds in the clusters. Outlined in (A) are glucocorticoids, outlined in (D) are cephalosporins.
* indicates compounds which appear in Table 1 or 2.
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transfection at the 5 mM concentration. A majority of the screened flu-
oroquinolones and macrolides were identified as hits that produced sig-
nificant fold-increase in transfection at 50 mM (Table 3), and a majority
of the screened fluoroquinolones, macrolides, and tetracyclines demon-
strated significant fold-increase in transfection at 5 mM (Table 3).
3.2 | Flavonoids and stilbenoids
Four of the ten compounds that showed the largest fold-decrease in
transfection at 50 mM in the screen are flavonoids (Table 2), with trans-
fection fold-decreases ranging from 0 to 0.36, and associated cell-
count and Hoechst intensity fold-changes ranging from 0.8 to 1.68-
fold and 0.86 to 0.87-fold, respectively. One of these flavonoids,
EGCG, also showed 0.08, 1.37, and 0.88 fold-changes in transfection,
cell-count, and Hoechst-intensity, respectively, at 5 mM (Table 1). At 5
mM, nobiletin was one of the ten compounds that showed the highest
fold-increase in transfection, with fold-changes of 2.08, 0.61, 1.23, and
1.21 in transfection, cell-count, Hoechst-intensity, and resazurin-
intensity, respectively (Table 1).
Stilbenoids demonstrated among the highest fold-increases in
transfection observed in the screen. Piceid was one of the ten com-
pounds that showed the highest fold-increase in transfection at 50 mM
(Table 2), with fold-changes of 2.63, 0.69, and 1.17, in transfection,
cell-count, and Hoechst-intensity, respectively, while resveratrol was
one of the ten compounds that showed the highest fold-increases in
transfection at 5 mM (Table 1), with fold-changes of 3.04 and 0.55, in
transfection and cell-count, respectively.
3.3 | GABAA receptor modulators
GABAA receptor modulators demonstrated among the highest fold-
increases to transfection in the screen at both 5 and 50 mM. No
GABAA receptor modulators were identified as hits for fold-decreases
in transfection. Stiripentol was one of the ten compounds that showed
the highest fold-increase in transfection at 50 mM (Table 2), with fold-
changes of 1.77, 0.72, and 1.23, in transfection, cell-count, and
Hoechst-intensity, respectively. Zolpidem tartrate and nitrazepam were
two of the ten compounds that showed the highest fold-increase in
transfection at 5 mM (Table 1), with fold-changes of 3.05 and 2.03, and
0.52 and 0.53, in transfection and cell-count, respectively. From the
clustering perspective, a majority of the compounds in the GABAA
modulator cluster were hits exhibiting fold-increases in transfection at
5 mM (Table 3).
3.4 | Hormones
The hormone cluster had the most member compounds of all clusters
in the NCC collection, with 54 members, 30 of which are glucocorti-
coids. From the clustering perspective, the majority of glucocorticoids
and hormones demonstrated fold-increases in transfection at 5 mM
(Table 3). However, hormones were not among the compounds with
largest fold-increases or fold-decreases in transfection in the screen
(Tables 1 and 2).
4 | DISCUSSION
Nonviral gene delivery methods are not currently competitive with viral
transduction in clinical trials.10 Pharmaceutical priming has been shown
to improve transfection efficiency,11–19 although in the case of gluco-
corticoids for example, their priming mechanisms are not well under-
stood. Transfection priming effects of certain compounds are also likely
to be cell type and carrier specific, so there is a need to search for
more classes of priming compounds to generate a library of transfec-
tion priming candidates and better understand tunable priming mecha-
nisms. Preliminary research into transfection priming should seek
compounds that have a low development cost and are known to be
biocompatible and bioavailable. The particular collection of pharmaco-
logical compounds screened was the NCC from the NIH Small Mole-
cule Repository,20 which is provided to researchers to repurpose
clinically approved pharmaceutical compounds. NCC compounds have
known drug-like properties, with well-studied bioactivity, making the
NCC an ideal starting point for a high-throughput screen to discover
priming compounds for nonviral gene delivery.
4.1 | Overall screen results
Of the 725 NCC compounds screened for their effect on transfection,
hundreds had significant effects on transfection at 5 or 50 mM doses,
of which the most effective priming compounds were identified and
examined for clustered effects of several drug classes. The highest con-
centration tested in this screen was 50 lM, which was based on a pre-
vious high throughput screen that similarly screened, in vitro, for novel
chemoprotective compounds at 50 lM.24 Additional concentrations at
orders of magnitude lower concentration (5 and 0.5 lM) were consid-
ered in order to test for compounds which require more dilute concen-
trations to affect transfection fold-changes with minimal cytotoxicity.
In preliminary screens carried out at 0.5, 5, and 50 lM in our lab (data
not shown), the majority of potential hits were identified at 5 and 50
lM, therefore, these two concentrations were chosen for the complete
NCC screen.
It must be emphasized that within this screen, the priming com-
pounds and PEI/DNA complexes were in fact not added at the same
time, with the priming compounds delivered to cells 1 hr prior to deliv-
ery of the PEI/DNA complexes. This timing was selected based on pre-
vious studies,15–19 which demonstrated that priming compound effects
do not require codelivery with the transfection, and in fact were often
most potent when applied in a short window of time, including the 1-
hr time point, prior to transfection. The screen was conducted in dupli-
cate (n52) with normalization of transfection measures to minimize
artifacts.
Preliminary verification experiments were performed for three of
the priming compounds identified: resveratrol, corticosterone, and epi-
gallocatechin gallate. Resveratrol and EGCG were chosen to verify anti-
oxidants, a drug class that demonstrated among the largest
transfection fold-changes observed in the screen; furthermore, these
two drugs demonstrated opposite effects on transfection, given resver-
atrol was shown to increase transfection in the screen (3-fold at 5 lM),
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while EGCG knocked down transfection (13-fold at 5 lM) in the
screen. Corticosterone was chosen as one of the glucocorticoid hor-
mones in the NCC, a large class of priming compounds that exhibited
modest transfection fold-increases (corticosterone: 1.5-fold at 5 lM) in
the screen. In the verification experiments, these compounds were
tested in triplicate at 5 lM, with resveratrol exhibiting approximately
5-fold increase in transfection relative to control, corticosterone exhib-
iting approximately 3.5-fold increase, and EGCG exhibiting 38-fold
decrease; these further experiments agree with the screen results (see
Supporting Information Figures S1 and S2).
There was a negative correlation in screen hits between transfec-
tion fold-increases and cell-count fold-change, which may be related to
interference of priming compounds with normal cell processes, or
increased toxicity of EGFP as it is overproduced due to priming. Drug
clustering results indicate that certain compounds may be modulating
the cell response to PEI transfection; those clusters include antibiotics,
antioxidants, GABAA modulators, and glucocorticoids, as discussed
next.
4.2 | Antibiotics
From the results of the screen, antibiotic priming compounds were
shown to affect transfection, with many showing potent inhibition
(Table 2). Many protocols recommend transfection in medium without
antibiotics, as they are thought to decrease transfection or cell viabil-
ity.25,26 However, among the antibiotics in the NCC, antibiotic effects
on transfection were observed to be dose and antibiotic-class depend-
ent. At 50 mM, the majority of cephalosporin- and tetracycline-class
antibiotics screened resulted in large fold-decreases in transfection
(Table 3), while the fluoroquinolone-class did not show transfection
fold-decreases at 50 mM. At 5 mM, the majority of antibiotics in the
fluoroquinolone-, macrolide-, and tetracycline-class clusters resulted in
transfection fold-increases; the majority of b-lactam/cephalosporin
cluster antibiotics did not prime transfection fold-increases at 5 mM.
The mechanisms that cause the transfection priming effects of
antibiotics observed in the screen may be related to the primary off-
target of antibiotics in mammalian host cells, which is mitochondria.27
Modulation of mitochondrial dysfunction and oxidative stress response
could explain the effects antibiotics have on transfection, particularly
when utilizing transfection reagents that are known to affect mitochon-
dria, such as PEI. PEI has been shown to cause mitochondrial dysfunc-
tion through disruption of the mitochondrial membrane that can result
in oxidative stress and apoptosis.28 If the identified antibiotic classes
are inducing their priming effects through interaction with mitochon-
dria, it would be evidence that PEI-induced mitochondrial dysfunction
and associated autophagy can be modulated to either increase or
decrease transfection by design of the priming compound.
4.3 | Flavonoid and stilbenoid compounds
The priming effects observed in antioxidants tested from the NCC in
this screen provide further evidence that modulation of mitochondrial
dysfunction is a potent priming mechanism of PEI transfection. The fla-
vonoid nobileton showed 2-fold increase in transfection at 5 mM,
among the largest in the screen. Conversely, several flavonoids were
among compounds with largest fold-decrease in transfection at 50 mM;
EGCG exhibited the most potent fold-decrease in transfection of the
screen at both 5 and 50 mM, with fold-decreases of 0.08 and 0, and
cell-count fold-changes of 1.37 and 0.8, respectively (Tables 1 and 2).
The stilbenoids resveratrol and piceid, at 5 and 50 mM, respectively,
exhibited nearly 3-fold increases in transfection, which were among
the largest seen in the screen.
Like antibiotics, antioxidant transfection priming effects observed
in the screen can potentially be explained by interactions with mito-
chondria, however, in a manner that generally protects or improves
their function.29 Resveratrol is a natural phenol, specifically a stilbenoid,
with antioxidant properties, that can be found in grape skins.29 Piceid
is a another plant-derived stilbenoid, specifically a glucoside modifica-
tion of resveratrol. Resveratrol has been shown to rescue mitochon-
drial dysfunction and modulate autophagy,30 which could be beneficial
by mitigating the cytotoxic effects of PEI transfection,28 from PEI’s
toxic interactions with mitochondria, to oxidative stress induced by
transgene expression.16–19,31 If antioxidants are modulating transfec-
tion through mitochondria and oxidative stress response,32 the
observed antioxidant priming effects that potently increase or decrease
transfection provide additional evidence that the cellular stress
response to transfection is critical to overall transfection outcome,16–18
a response that is tunable by priming.
4.4 | GABAA receptor modulators
Like antibiotics and antioxidants, GABAA modulators were also identi-
fied by the screen as compound clusters in the NCC that resulted in
large transfection fold-changes, with the majority of GABAA modula-
tors (seven of nine compounds) increasing transfection at the 5 mM
concentration. Zolpidem, nitrazepam, and stiripentol were identified to
cause among the highest transfection fold-increases in in the screen: 3,
2, and 1.7-fold, respectively (Tables 1 and 2).
GABAA receptors are neurotransmitter receptors that are not
expressed in most cell types, so the mechanism behind priming effects
seen with the GABAA modulator cluster is not immediately apparent.
Benzodiazepines, stiripentol, and zolpidem are positive allosteric modu-
lators of the GABAA receptor found in neurons, however, they are
thought to act on different subunits.33,34 The GABAA receptor, or
some of the subunits, may be expressed in HEK293T cells, a plausible
possibility due to the proposed adrenal cortex origin of the HEK293T
cell line,35 which may explain the observed transfection priming effects
of GABAA modulators in the screen, although the potential mechanism
of interaction between GABAA receptor modulation and transfection
is not clear.
Another possibility that may explain the transfection priming
effects of GABAA modulators is interaction with the translocator pro-
tein, also known as the peripheral benzodiazepine receptor, which is
found in mitochondria membranes, and is thought to be involved in
steroidogenesis and redox regulation of mitophagy.36,37 This interac-
tion would be consistent with the concept of modulating mitochondrial
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dysfunction and cellular stress response to transfection as the mecha-
nism by which priming is occurring through antibiotics and antioxidants
(see above).
4.5 | Glucocorticoids and other hormones
Finally, the effects of glucocorticoids and other hormones in the NCC
were examined, as glucocorticoids have previously shown enhance-
ment of lipoplex-mediated transfection in hMSCs by over 10-fold.15
The hormone cluster was the largest cluster of drugs in the NCC, and
the majority of these hormones were glucocorticoids (Figure 2). In this
screen, the majority of hormones, and glucocorticoids specifically,
increased transfection at the 5 mM concentration, with average 1.4-
fold increases in transfection. This transfection fold-change is much
less than the 10-fold increases seen previously in hMSCs15 indicating
priming effects for at least certain compounds are dependent on cell
type and/or transfection reagent.
There are several plausible explanations for the transfection pri-
ming fold-increases observed in glucocorticoids and other hormones in
this screen. Glucocorticoids are hormones that are involved in the
body’s stress response, activating the glucocorticoid receptor, which
translocates to the nucleus and acts as a transcription factor.15 Upregu-
lation of certain genes by activated hormone receptors in response to
priming by hormones may play a role in the observed transfection fold-
changes in the screen, as it has previously been shown in gene expres-
sion profiling studies that pharmacological priming of genomic targets
can affect transfection.16–19 Activated glucocorticoid receptors may
also play a role in priming transfection by assisting internalization,
nuclear transport, and nuclear import of transfection complexes.
Finally, glucocorticoid priming effects in PEI transfection could be
occurring through interaction with mitochondria and autophagy,38,39
which would be further evidence that aligns with the hypothesis that
modulation of PEI transfection toxicity and cellular stress response are
the priming mechanisms for antibiotics, antioxidants, and GABAA
clusters.
4.6 | Mitochondrial dysfunction, oxidative stress, and
autophagy in PEI transfection
PEI is a cationic polymer carrier for nonviral gene delivery that serves
as a standard to which newly developed carriers are often compared,
as it reliably overcomes the primary barriers to transfection of cultured
mammalian cells: internalization, endosomal escape, and nuclear trans-
port,8 although not with the efficiencies found in viral vectors.9 Para-
doxically, PEI designs that are more effectively able to overcome
barriers to transfection also tend to be more toxic to the transfected
cell. For instance, high molecular weight (MW) and branched PEI com-
plexes have been demonstrated to transfect at higher efficiencies com-
pared to low MW and linear PEI complexes,40,41 but also exhibit higher
toxicity. Attempts to resolve this dilemma include bioresponsive link-
ages of low MW PEI into higher MW PEI-based polymers that will
degrade in the cell into less toxic lower MW constituents.40
PEI has been shown to be cytotoxic through its accumulation in
and interaction with mitochondrial membranes.28 Damage to mito-
chondria has been implicated in the intracellular inflammatory and
immune response42,43; PEI has been shown to be an effective adjuvant
for stimulating an immune response.44 Typical cellular responses to
mitochondrial damage are autophagy/mitophagy, apoptosis, and necro-
sis. Apoptosis and autophagy are mutually inhibitory,45 with apoptosis
leading to cell death, while autophagy possibly serves a protective role
in PEI cytotoxicity.46
Altogether, literature review of grouped screen hit compounds
suggests that many priming effects may be due to modulation of the
cellular oxidative stress response to PEI transfection, in particular mito-
chondrial dysfunction. It is plausible that certain antioxidants like
resveratrol29,30 rescue the cell from PEI-induced mitochondrial dys-
function through modulation of autophagy, improving transfection,
while certain antibiotics that reduce transfection, such as cephalospo-
rins,47 may be inhibiting transfection by increasing mitochondrial dys-
function and oxidative stress.
Gene expression profiling has shown that there is differential
expression in the cellular oxidative stress response associated with suc-
cessfully versus unsuccessfully PEI-transfected cells, through ATF3,
IREB2, and other gene pathways.16–19 The high-throughput screen
data in this current study support this finding, and suggest that modu-
lating the cellular stress response to PEI transfection by priming with
clinically approved compounds prior to PEI transfection can signifi-
cantly affect overall transfection efficiency and transgene expression in
vitro.
5 | CONCLUSIONS
With a high-throughput, drug-repurposing, and bio/cheminformatics
clustering approach, this screen of the NCC identified many individual
compounds that produce dramatic fold-changes in HEK293T transfec-
tion by PEI, and several classes of clinical drugs for which the majority
of compounds demonstrated priming effects. These hit compounds
and drug clusters should be verified and studied for investigation of
the priming mechanisms in detail that will improve our understanding
of the cellular response to transfection and how this response can be
pharmacologically modulated to improve transfection. The clustered
data suggest that several of these drug classes, such as stilbenoids and
flavonoid antioxidants, cephalosporin antibiotics, GABAA receptor
modulators, and others, may be priming transfection through modula-
tion of mitochondrial dysfunction, oxidative stress, and cell death proc-
esses caused by toxicity of PEI transfection. These compounds and
drug classes should be tested on additional cell types with alternative
nonviral carriers to generalize the priming effects towards potential
application as transfection adjuvants. For future in vivo studies, the 5
and 50 lM concentrations can serve as starting points in the optimiza-
tion of the delivery method and dose and release characteristics of
each priming compound to maximize transfection priming effects. Addi-
tionally, timing of the addition of the priming compound relative to the
DNA should be studied more extensively as a tunable priming
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parameter. Resveratrol and zolpidem had the highest fold-change
increases observed in the screen, at 3-fold; the potency of their priming
effect indicates their mechanisms may be critical to understanding how
nonviral gene delivery can be improved by priming.
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